Secukinumab demonstrates sustained efficacy in moderate to severe plaque psoriasis across disease severity subgroups

被引：0
|
作者：
Spelman, L. [1 ]
Blauvelt, A. [2 ]
Loffler, J. [3 ]
Papavassilis, C. [3 ]
Fox, T. [3 ]
机构：
[1] Verac Clin Res, Woolloongabba, Qld, Australia
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Novartis Pharma AG, Basel, Switzerland
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [1] Secukinumab demonstrates sustained efficacy in moderate to severe plaque psoriasis across disease severity subgroups
    Spelman, Lynda
    Blauvelt, Andrew
    Loeffler, Juergen
    Papavassilis, Charis
    Fox, Todd
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB248 - AB248
  • [2] Efficacy and safety of secukinumab in moderate to severe plaque psoriasis
    Aparicio Rubio, Celia
    Monteagudo Santolaya, Emilio
    Cornejo Uixeda, Silvia
    Prieto Castello, Manuel
    Antonino de la Camara, Gonzalo
    Quintana Vergara, Belen
    Sanchez Alcaraz, Agustin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 299 - 299
  • [3] Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
    Garnock-Jones, Karly P.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2015, 16 (04) : 323 - 330
  • [4] Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
    Karly P. Garnock-Jones
    American Journal of Clinical Dermatology, 2015, 16 : 323 - 330
  • [5] Secukinumab demonstrates high sustained efficacy and a favourable safety profile through 5 years of treatment in moderate to severe psoriasis
    Mate, E.
    Bissonnette, R.
    Luger, T.
    Thaci, D.
    Toth, D.
    Lacombe, A.
    Xia, S.
    Mazur, R.
    Patekar, M.
    Charef, P.
    Milutinovic, M.
    Leonardi, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 86 - 86
  • [6] Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
    Blair, Hannah A.
    PEDIATRIC DRUGS, 2021, 23 (06) : 601 - 608
  • [7] Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
    Hannah A. Blair
    Pediatric Drugs, 2021, 23 : 601 - 608
  • [8] Secukinumab demonstrates sustained effectiveness in treating patients with moderate-to-severe plaque psoriasis: real-world evidence from Canada
    Papp, K. A.
    Gooderham, M.
    Delorme, I.
    Lomaga, M.
    Robern, M.
    Hernandez, M. A.
    Taraska, V.
    Ho, V.
    Vieira, A.
    Rihakova, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 44 - 45
  • [9] Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
    Cai Lin
    Zhang Jian-Zhong
    Yao Xu
    Gu Jun
    Liu Quan-Zhong
    Zheng Min
    Zhang Shi-Fa
    Xu Jin-Hua
    Li Cheng-Xin
    Cheng Hao
    Guo Qing
    Pan Wei-Li
    Li Shen-Qiu
    Li Ruo-Yu
    Guo Zai-Pei
    Song Zhi-Qi
    Li Shan-Shan
    Dong Xiu-Qin
    Wang Linda
    Fu Rong
    Regnault Pascaline
    Charef Pascal
    Mazur Rafal
    Patekar Manmath
    中华医学杂志英文版, 2020, 133 (22) : 2665 - 2673
  • [10] Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
    Cai, Lin
    Zhang, Jian-Zhong
    Yao, Xu
    Gu, Jun
    Liu, Quan-Zhong
    Zheng, Min
    Zhang, Shi-Fa
    Xu, Jin-Hua
    Li, Cheng-Xin
    Cheng, Hao
    Guo, Qing
    Pan, Wei-Li
    Li, Shen-Qiu
    Li, Ruo-Yu
    Guo, Zai-Pei
    Song, Zhi-Qi
    Li, Shan-Shan
    Dong, Xiu-Qin
    Wang, Linda
    Fu, Rong
    Regnault, Pascaline
    Charef, Pascal
    Mazur, Rafal
    Patekar, Manmath
    CHINESE MEDICAL JOURNAL, 2020, 133 (22) : 2665 - 2673
12345